SCHEMBL29800777

SCHEMBL29800777

Cc1cccnc1S(=O)(=O)Nc1cccc2c1CN(C)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 8/20 0.42
▸ ALDH1A1 P00352 4/20 0.40
▸ KMT2A Q03164 5/20 0.39
▸ TDP1 Q9NUW8 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ P2RY1 P47900 1/20 0.38
▸ LMNA P02545 4/20 0.38
▸ HTT P42858 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ S1PR4 O95977 2/20 0.38
▸ S1PR1 P21453 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ MITF O75030 1/20 0.38
▸ AGTR1 P30556 1/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ CKS1B P61024 1/20 0.38
▸ SKP2 Q13309 1/20 0.38
▸ GLO1 Q04760 1/20 0.37
▸ CARM1 Q86X55 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26964253 1.00 SLC40A1 (0.42) SLC40A1ALDH1A1KMT2ATDP1MEN1
SCHEMBL29800820 0.90 ALDH1A1 (0.43) SLC40A1ALDH1A1KMT2ATDP1MEN1
SCHEMBL26964182 0.90 ALDH1A1 (0.43) SLC40A1ALDH1A1KMT2ATDP1MEN1
SCHEMBL30925503 0.84 SLC40A1 (0.39) SLC40A1ALDH1A1KMT2ATDP1MEN1
SCHEMBL30925565 0.80 SLC40A1 (0.43) SLC40A1ALDH1A1KMT2ATDP1MEN1
SCHEMBL27214238 0.80 SLC40A1 (0.43) SLC40A1ALDH1A1KMT2ATDP1MEN1
SCHEMBL26964299 0.79 NPSR1 (0.44) SLC40A1ALDH1A1LMNAHTTNPSR1
SCHEMBL30925408 0.79 ALDH1A1 (0.40) SLC40A1ALDH1A1KMT2ATDP1MEN1
SCHEMBL30553464 0.78 KMO (0.43) SLC40A1ALDH1A1KMT2ATDP1MEN1
SCHEMBL26964398 0.78 KMO (0.43) SLC40A1ALDH1A1KMT2ATDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed
EP-4291555-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-12-20 — — EP disclosed
CN-116806218-A Sulfonamide and its use for the treatment of parasitic helminth infections and diseases 新基公司 2023-09-26 — — CN disclosed
WO-2022173727-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885ALDH1A1 1470/4885KMT2A 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback